3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Mesothelioma
2
Carcinoma, Non-Small-Cell Lung
2
Neoplasms
1
Mesothelioma, Malignant
1
Interventions
Cisplatin
30
Pemetrexed
21
Gemcitabine
11
Radiotherapy
6
Nivolumab
6
Drug Therapy
6
Cyclophosphamide
6
Carboplatin
6
durvalumab
4
Vinorelbine
4
Chemotherapy, Adjuvant
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
sodium thiosulfate
3
sargramostim
3
Ipilimumab
3
Doxorubicin
3
raltitrexed
2
pembrolizumab
2
cediranib
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Psychiatric Rehabilitation
2
Photochemotherapy
2
Neoadjuvant Therapy
2
Methotrexate
2
Interferon-alpha
2
Imatinib Mesylate
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma, Malignant
×
amatuximab
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts